Cell-therapy due diligence for patients in Israel
A country-specific starting point for checking product authorisation, trial oversight and cross-border follow-up. This page does not rank providers or recommend medical travel.
What the regulator can confirm
In Israel, the Ministry of Health is the official starting point for questions about medicines, clinical research and licensed healthcare activity. Academic research strength or a provider's professional registration does not establish that a particular cell product is authorised for routine treatment.
Ask for the exact product, manufacturing site, indication and legal route. For a trial, verify the sponsor, protocol, ethics and regulatory approvals and current recruitment status. For treatment abroad, have an independent Israeli specialist review the proposal and agree who will manage complications and follow-up.
Evidence to request before treatment
| Question | Document or identifier | Why it matters |
|---|---|---|
| What exactly is administered? | Product name, cell source, processing, dose and route | Evidence and legal status are product- and indication-specific. |
| What is the legal route? | Marketing authorisation, authorised trial number, or named exemption and authority | A clinic licence or registry listing does not by itself authorise a product. |
| Who manufactures it? | Legal manufacturer, site and authorisation scope | General references to GMP are not a substitute for a current, applicable record. |
| How are harms managed? | Consent form, adverse-event plan, insurance and emergency contact | Experimental status does not remove the duty to disclose and manage risk. |
| What happens after travel? | Written follow-up plan and named clinician | Cross-border care can complicate continuity and reporting. |
Conditions compared
Educational regulatory orientation, reviewed in 2026. Verify current records directly with the authority and seek independent medical advice.